Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Intelligent Capsule to Enable Noninvasive Sampling of Intestinal Microorganisms

By BiotechDaily International staff writers
Posted on 15 Apr 2013
Print article
Image: The IntelliCap capsule (Photo courtesy of Medimetrics Personalized Drug Delivery BV).
Image: The IntelliCap capsule (Photo courtesy of Medimetrics Personalized Drug Delivery BV).
Two Dutch companies are collaborating on a project that will establish a noninvasive method for studying how foods and food additives affect the microbes that regulate the digestive process in the small intestine.

NIZO Food Research (Ede, [Food Valley], The Netherlands) and Medimetrics (Eindhoven, The Netherlands) are generating new applications for the Medimetrics' IntelliCap system, which is currently used by the pharmaceutical industry for the targeted and controlled delivery of drugs in the human gastrointestinal tract.

The IntelliCap capsule is a tiny, pill-shaped (11 x 26 mm) microelectronic instrument that is swallowed by the test subject. The capsule then passes through the digestive tract by peristalsis. Samples, which are documented by transit time, pH level, and temperature, are collected and held in separate compartments

After being excreted by the test subject, a quantitative and representative map of each sample’s microbiological molecular composition will be generated using methodology developed by NIZO.

“By assessing the way food and probiotics affect microbiota composition inside the small intestine of healthy individuals, we can better decipher the mechanisms which influence gut health, host metabolism, and immunity,” said Dr. Harro Timmerman, a principle researcher at NIZO. “We may even access new markers which enable us to substantiate claims regarding the health properties of certain foods.”

Dr. Christoph Wanke, clinical program leader at Medimetrics, said, “Food scientists wanting to develop functional foods immediately see the potential of the IntelliCap technology in enabling them to apply it as a novel tool to characterize the gut microbiome. In addition, considering its established functionality as a targeted, oral delivery device, we can see further extensions of the technology in relation to health and disease. This offers the potential to explore novel therapeutic approaches which would enable clinicians to control the microbiological composition of the gut in the treatment of diseases like obesity and diabetes.”

Related Links:
NIZO Food Research
Medimetrics


Print article

Channels

Genomics/Proteomics

view channel
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).

Statins May Help Block Transmission of Lyme Disease

A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease. Lyme disease... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.